SVNS — Solvonis Therapeutics Share Price
Last trade - 00:00- £3.50m
- £2.74m
- 24
- 22
- 43
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 3.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.84% | ||
| Return on Equity | -56.63% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | 0.22 | 0.54 | 0.59 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC, is a United Kingdom-based biotechnology company. The Company is focused on developing intellectual property related to the treatment of mental health and substance-use disorders, and co-developing therapeutics for these conditions. It focuses on improving outcomes for individuals suffering from these disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD is a debilitating mental health condition characterized by persistent and distressing symptoms following exposure to traumatic events.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 18th, 2017
- Public Since
- January 6th, 2022
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 2,295,930,633
- Address
- Eccleston Yards, 25 Eccleston Place, LONDON, SW1W 9NF
- Web
- https://graftpolymer.co.uk/
- Phone
- Auditors
- Kreston Reeves LLP
Latest News for SVNS
Upcoming Events for SVNS
Similar to SVNS
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 23:20 UTC, shares in Solvonis Therapeutics are trading at 0.15p. This share price information is delayed by 15 minutes.
Shares in Solvonis Therapeutics last closed at 0.15p and the price had moved by +8.93% over the past 365 days. In terms of relative price strength the Solvonis Therapeutics share price has outperformed the FTSE All Share Index by +5.94% over the past year.
There is no consensus recommendation for this security.
Find out moreSolvonis Therapeutics does not currently pay a dividend.
Solvonis Therapeutics does not currently pay a dividend.
Solvonis Therapeutics does not currently pay a dividend.
To buy shares in Solvonis Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 0.15p, shares in Solvonis Therapeutics had a market capitalisation of £3.50m.
Here are the trading details for Solvonis Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SVNS
Based on an overall assessment of its quality, value and momentum Solvonis Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Solvonis Therapeutics. Over the past six months, its share price has outperformed the FTSE All Share Index by +12.42%.
As of the last closing price of 0.15p, shares in Solvonis Therapeutics were trading -14.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Solvonis Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.15p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Solvonis Therapeutics' directors